Table 1 A summary of the clinicopathologic variables in all cohorts.
TCGA-LUAD (D1) | TCGA-LUSC (D2) | Yale-LUAD (D3) | Yale-LUSC (D4) | UBern-LUAD (D5) | CA209-057-LUAD (D6Nivolumab) | CA209-057-LUAD (D6Docetaxel) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Subgroups or values | Training n (%) | Testing n (%) | Training n (%) | Testing n (%) | CV n (%) | CV n (%) | External validation n (%) | External validation n (%) | External validation n (%) |
Gender | Male | 133 (45.2) | 53 (41.7) | 225 (73.5) | 104 (78.8) | 27 (43.5) | 15 (71.4) | 50 (50.0) | 87 (54.0) | 77 (55.0) |
Female | 161 (54.8) | 74 (58.3) | 81 (26.5) | 28 (21.2) | 35 (56.5) | 6 (28.6) | 50 (50.0) | 75 (46.0) | 64 (45.0) | |
Tumor stage | Stage I | 157 (53.4) | 70 (55.1) | 137 (44.8) | 73 (55.3) | 37 (59.6) | 14(66.7) | 9 (9.0) | 0 (0) | 0 (0) |
Stage II | 80 (27.2) | 28 (22.0) | 106 (34.6) | 36 (27.3) | 5 (8.1) | 7 (33.3) | 11 (11.0) | 0 (0) | 0 (0) | |
Stage III | 40 (13.6) | 18 (14.2) | 55 (18.0) | 21 (15.9) | 16 (25.8) | 0 (0) | 70 (70.0) | 10 (6.2) | 13 (9.2) | |
Stage IV | 13 (4.4) | 9 (7.1) | 5 (1.6) | 1 (0.8) | 4 (6.5) | 0 (0) | 10 (10.0) | 152 (93.8) | 128 (90.8) | |
Unknown | 4 (1.4) | 2 (1.6) | 3 (1.0) | 1 (1.8) | N/A | N/A | N/A | 0 (0) | 0 (0) | |
Mean age | years | 65 ± 10.1 | 66 ± 9.7 | 67 ± 8.8 | 68 ± 7.6 | 64 ± 10.5 | 64 ± 7.2 | 62 ± 9.7 | 60 ± 8.9 | 62 ± 8.9 |
Mean overall survival time | days | 948 ± 971 | 864 ± 708 | 992 ± 984 | 931 ± 924 | 1084 ± 854 | 2085 ± 958 | 911 ± 644 | 635 ± 656 | 437 ± 451 |
